{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:25:54Z","timestamp":1795029954814,"version":"4.10.2"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073796, 81627901"],"award-info":[{"award-number":["82073796, 81627901"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272844, 81974459"],"award-info":[{"award-number":["82272844, 81974459"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited number of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, especially stem-like CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, in tumor tissues. Here we develop engineered microparticles (MPs) derived from alpha-fetoprotein (AFP)-overexpressing macrophages to load resiquimod (R848@M2pep-MPs\n                    <jats:sub>AFP<\/jats:sub>\n                    ) for enhanced anti-PD-1 therapy in HCC. R848@M2pep-MPs\n                    <jats:sub>AFP<\/jats:sub>\n                    target and reprogram immunosuppressive M2-like tumor-associated macrophages (TAMs) into M1-like phenotype. Meanwhile, R848@M2pep-MPs\n                    <jats:sub>AFP<\/jats:sub>\n                    -reprogrammed TAMs act as antigen-presenting cells, not only presenting AFP antigen to activate CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell-mediated antitumor immunity, but also providing an intra-tumoral niche to maintain and differentiate stem-like CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Combination immunotherapy with anti-PD-1 antibody generates strong antitumor immune memory and induces abundant stem-like CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell proliferation and differentiation to terminally exhausted CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells for long-term immune surveillance in orthotopic and autochthonous HCC preclinical models in male mice. We also show that the R848-loaded engineered MPs derived from macrophages overexpressing a model antigen ovalbumin (OVA) can improve anti-PD-1 therapy in melanoma B16-OVA tumor-bearing mice. Our work presents a facile and generic strategy for personalized cancer immunotherapy to boost anti-PD-1 therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-41438-9","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:01:59Z","timestamp":1694592119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Xiaoqiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-9798","authenticated-orcid":false,"given":"Tuying","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-0493","authenticated-orcid":false,"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-8763","authenticated-orcid":false,"given":"Xiangliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-867X","authenticated-orcid":false,"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"41438_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"41438_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"41438_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","volume":"18","author":"F Zhou","year":"2021","unstructured":"Zhou, F., Qiao, M. & Zhou, C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol. Immunol. 18, 279\u2013293 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"41438_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/acs.accounts.0c00339","volume":"53","author":"X Han","year":"2020","unstructured":"Han, X., Li, H., Zhou, D., Chen, Z. & Gu, Z. Local and targeted delivery of immune checkpoint blockade therapeutics. Acc Chem. Res. 53, 2521\u20132533 (2020).","journal-title":"Acc Chem. Res."},{"key":"41438_CR5","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"41438_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193\u2013202 (2020).","journal-title":"J. Clin. Oncol."},{"key":"41438_CR7","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins, L. et al. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 82, 2904\u20132917 (2022).","journal-title":"Cancer Res."},{"key":"41438_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"41438_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","volume":"22","author":"F Baharom","year":"2021","unstructured":"Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. 22, 41\u201352 (2021).","journal-title":"Nat. Immunol."},{"key":"41438_CR10","doi-asserted-by":"publisher","first-page":"eabo7604","DOI":"10.1126\/scitranslmed.abo7604","volume":"14","author":"AM D\u2019Alise","year":"2022","unstructured":"D\u2019Alise, A. M. et al. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci. Transl. Med. 14, eabo7604 (2022).","journal-title":"Sci. Transl. Med."},{"key":"41438_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy? Nat. Rev. Immunol. 20, 128\u2013136 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"41438_CR12","doi-asserted-by":"publisher","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","volume":"11","author":"W Jiang","year":"2020","unstructured":"Jiang, W. et al. Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 11, 622509 (2020).","journal-title":"Front Immunol."},{"key":"41438_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211. e110 (2019).","journal-title":"Immunity"},{"key":"41438_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"41438_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"41438_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830. e814 (2018).","journal-title":"Immunity"},{"key":"41438_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"41438_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"41438_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20723-x","volume":"12","author":"Z Wei","year":"2021","unstructured":"Wei, Z. et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat. Commun. 12, 440 (2021).","journal-title":"Nat. Commun."},{"key":"41438_CR20","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986\u2013994 (2016).","journal-title":"Nat. Nanotechnol."},{"key":"41438_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889\u2013896 (2010).","journal-title":"Nat. Immunol."},{"key":"41438_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"M De Palma","year":"2013","unstructured":"De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277\u2013286 (2013).","journal-title":"Cancer Cell"},{"key":"41438_CR23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41565-021-00988-z","volume":"16","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours. Nat. Nanotechnol. 16, 1394\u20131402 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"41438_CR24","doi-asserted-by":"publisher","first-page":"eaat1500","DOI":"10.1126\/scitranslmed.aat1500","volume":"11","author":"S Singhal","year":"2019","unstructured":"Singhal, S. et al. Human tumor-associated monocytes\/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci. Transl. Med. 11, eaat1500 (2019).","journal-title":"Sci. Transl. Med."},{"key":"41438_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"41438_CR26","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1172\/JCI97642","volume":"129","author":"D Muraoka","year":"2019","unstructured":"Muraoka, D. et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J. Clin. Invest. 129, 1278\u20131294 (2019).","journal-title":"J. Clin. Invest."},{"key":"41438_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/13543784.2013.749236","volume":"22","author":"T Meyer","year":"2013","unstructured":"Meyer, T., Surber, C., French, L. E. & Stockfleth, E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin. Investig. Drugs 22, 149\u2013159 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"41438_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196\u2013200 (2002).","journal-title":"Nat. Immunol."},{"key":"41438_CR29","doi-asserted-by":"publisher","first-page":"120601","DOI":"10.1016\/j.biomaterials.2020.120601","volume":"268","author":"H Li","year":"2021","unstructured":"Li, H., Somiya, M. & Kuroda, S. Enhancing antibody-dependent cellular phagocytosis by re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. Biomaterials 268, 120601 (2021).","journal-title":"Biomaterials"},{"key":"41438_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22311-z","volume":"12","author":"B Bahmani","year":"2021","unstructured":"Bahmani, B. et al. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat. Commun. 12, 1999 (2021).","journal-title":"Nat. Commun."},{"key":"41438_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1242\/dmm.027409","volume":"10","author":"MG Hasham","year":"2017","unstructured":"Hasham, M. G. et al. Systemic autoimmunity induced by the TLR7\/8 agonist resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease. Dis. Model Mech. 10, 259\u2013270 (2017).","journal-title":"Dis. Model Mech."},{"key":"41438_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36321-6","volume":"14","author":"V Turco","year":"2023","unstructured":"Turco, V. et al. T cell-independent eradication of experimental glioma by intravenous TLR7\/8-agonist-loaded nanoparticles. Nat. Commun. 14, 771 (2023).","journal-title":"Nat. Commun."},{"key":"41438_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell, C. B. et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578\u2013588 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"41438_CR34","doi-asserted-by":"publisher","first-page":"114450","DOI":"10.1016\/j.addr.2022.114450","volume":"188","author":"N Bie","year":"2022","unstructured":"Bie, N., Yong, T., Wei, Z., Gan, L. & Yang, X. Extracellular vesicles for improved tumor accumulation and penetration. Adv. Drug Deliv. Rev. 188, 114450 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"41438_CR35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jconrel.2020.09.028","volume":"328","author":"T Yong","year":"2020","unstructured":"Yong, T., Li, X., Wei, Z., Gan, L. & Yang, X. Extracellular vesicles-based drug delivery systems for cancer immunotherapy. J. Control Release 328, 562\u2013574 (2020).","journal-title":"J. Control Release"},{"key":"41438_CR36","doi-asserted-by":"publisher","first-page":"e2201054","DOI":"10.1002\/adma.202201054","volume":"34","author":"T Yong","year":"2022","unstructured":"Yong, T., Wei, Z., Gan, L. & Yang, X. Extracellular-vesicle-based drug delivery systems for enhanced antitumor therapies through modulating the cancer-immunity cycle. Adv. Mater. 34, e2201054 (2022).","journal-title":"Adv. Mater."},{"key":"41438_CR37","doi-asserted-by":"publisher","first-page":"e2005562","DOI":"10.1002\/adma.202005562","volume":"33","author":"J Ding","year":"2021","unstructured":"Ding, J. et al. Self-activatable photo-extracellular vesicle for synergistic trimodal anticancer therapy. Adv. Mater. 33, e2005562 (2021).","journal-title":"Adv. Mater."},{"key":"41438_CR38","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.7150\/thno.45528","volume":"10","author":"L Guo","year":"2020","unstructured":"Guo, L. et al. Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2\/CCR2 signaling axis and promote drug delivery via SNARE-mediated membrane fusion. Theranostics 10, 6581\u20136598 (2020).","journal-title":"Theranostics"},{"key":"41438_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jhep.2010.06.027","volume":"54","author":"J Cany","year":"2011","unstructured":"Cany, J. et al. AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J. Hepatol. 54, 115\u2013121 (2011).","journal-title":"J. Hepatol."},{"key":"41438_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15569-2","volume":"11","author":"B Zuo","year":"2020","unstructured":"Zuo, B. et al. Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice. Nat. Commun. 11, 1790 (2020).","journal-title":"Nat. Commun."},{"key":"41438_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jhep.2017.05.019","volume":"67","author":"Z Lu","year":"2017","unstructured":"Lu, Z. et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J. Hepatol. 67, 739\u2013748 (2017).","journal-title":"J. Hepatol."},{"key":"41438_CR42","doi-asserted-by":"publisher","first-page":"15919","DOI":"10.1073\/pnas.1312197110","volume":"110","author":"M Cieslewicz","year":"2013","unstructured":"Cieslewicz, M. et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc. Natl Acad. Sci. USA 110, 15919\u201315924 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"41438_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2015.12.057","volume":"224","author":"C Ngambenjawong","year":"2016","unstructured":"Ngambenjawong, C., Cieslewicz, M., Schellinger, J. G. & Pun, S. H. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. J. Control Release 224, 103\u2013111 (2016).","journal-title":"J. Control Release"},{"key":"41438_CR44","doi-asserted-by":"publisher","first-page":"23684","DOI":"10.1073\/pnas.2002806117","volume":"117","author":"IX Chen","year":"2020","unstructured":"Chen, I. X. et al. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proc. Natl Acad. Sci. USA 117, 23684\u201323694 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"41438_CR45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41586-023-06132-2","volume":"618","author":"G Ortiz-Munoz","year":"2023","unstructured":"Ortiz-Munoz, G. et al. In situ tumour arrays reveal early environmental control of cancer immunity. Nature 618, 827\u2013833 (2023).","journal-title":"Nature"},{"key":"41438_CR46","doi-asserted-by":"publisher","first-page":"eaav7816","DOI":"10.1126\/scitranslmed.aav7816","volume":"11","author":"RM Zemek","year":"2019","unstructured":"Zemek, R. M. et al. Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci. Transl. Med. 11, eaav7816 (2019).","journal-title":"Sci. Transl. Med."},{"key":"41438_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","volume":"15","author":"M Locati","year":"2020","unstructured":"Locati, M., Curtale, G. & Mantovani, A. Diversity, mechanisms, and significance of macrophage plasticity. Annu. Rev. Pathol. 15, 123\u2013147 (2020).","journal-title":"Annu. Rev. Pathol."},{"key":"41438_CR48","doi-asserted-by":"publisher","first-page":"133847","DOI":"10.1016\/j.cej.2021.133847","volume":"433","author":"Z Wei","year":"2022","unstructured":"Wei, Z. et al. Engineered iron-based nanoplatform amplifies repolarization of M2-like tumor-associated macrophages for enhanced cancer immunotherapy. Chem. Eng. J. 433, 133847 (2022).","journal-title":"Chem. Eng. J."},{"key":"41438_CR49","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng, D. et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110, 11103\u201311108 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"41438_CR50","doi-asserted-by":"publisher","first-page":"eaat5690","DOI":"10.1126\/scitranslmed.aat5690","volume":"11","author":"M Guo","year":"2019","unstructured":"Guo, M. et al. Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci. Transl. Med. 11, eaat5690 (2019).","journal-title":"Sci. Transl. Med."},{"key":"41438_CR51","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"41438_CR52","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nri1245","volume":"3","author":"JB Huppa","year":"2003","unstructured":"Huppa, J. B. & Davis, M. M. T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3, 973\u2013983 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"41438_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","volume":"17","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat. Nanotechnol. 17, 531\u2013540 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"41438_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/cancers14010226","volume":"14","author":"K Arvanitakis","year":"2022","unstructured":"Arvanitakis, K., Koletsa, T., Mitroulis, I. & Germanidis, G. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers (Basel) 14, 226 (2022).","journal-title":"Cancers (Basel)"},{"key":"41438_CR55","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni, E. et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc. Natl Acad. Sci. USA 115, E4041\u2013E4050 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"41438_CR56","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5009\/gnl20223","volume":"15","author":"D Zhou","year":"2021","unstructured":"Zhou, D., Luan, J., Huang, C. & Li, J. Tumor-associated macrophages in hepatocellular carcinoma: friend or foe?. Gut Liver 15, 500\u2013516 (2021).","journal-title":"Gut Liver"},{"key":"41438_CR57","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the Efficacy of anti-PD-1 therapy. Immunity 50, 1498\u20131512. e1495 (2019).","journal-title":"Immunity"},{"key":"41438_CR58","doi-asserted-by":"publisher","first-page":"eaaw6071","DOI":"10.1126\/sciadv.aaw6071","volume":"6","author":"QQ Ni","year":"2020","unstructured":"Ni, Q. Q. et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci. Adv. 6, eaaw6071 (2020).","journal-title":"Sci. Adv."},{"key":"41438_CR59","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.nantod.2021.101195","volume":"38","author":"G Zhan","year":"2021","unstructured":"Zhan, G. et al. Biomimetic sonodynamic therapy-nanovaccine integration platform potentiates Anti-PD-1 therapy in hypoxic tumors. Nano Today 38, 101195 (2021).","journal-title":"Nano Today"},{"key":"41438_CR60","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41565-020-00782-3","volume":"15","author":"N Gong","year":"2020","unstructured":"Gong, N. et al. Proton-driven transformable nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 15, 1053\u20131064 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"41438_CR61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nnano.2017.113","volume":"12","author":"Y Min","year":"2017","unstructured":"Min, Y. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877\u2013882 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"41438_CR62","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","volume":"15","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 15, 1043\u20131052 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"41438_CR63","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2020.01.014","volume":"52","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity 52, 357\u2013373. e359 (2020).","journal-title":"Immunity"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41438-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41438-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41438-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:17:20Z","timestamp":1700198240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41438-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41438"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-41438-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5653"}}